LON:HIK

Hikma Pharmaceuticals Share Forecast, Price & News

GBX 2,387

-61.00 (-2.49 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

2,387

▼

2,454

50-Day Range

2,301

▼

2,512

52-Week Range

2,086.49

▼

2,768

Volume796,363 shs

Average Volume398,230 shs

Market Capitalization£5.52 billion

P/E Ratio18.59

Dividend Yield1.50%

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Drugs for Non-small Cell Lung Cancer Market Size and Share Research Report 2021 by Market Revenue, Industrial Chain Analysis and Forecast to 2026
June 16, 2021 | marketwatch.com

FTSE 100 creeps higher as index continues to sway in narrow range
June 10, 2021 | msn.com

Hikma Pharmaceuticals (LON:HIK) Stock Rating Reaffirmed by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell
June 8, 2021 | americanbankingnews.com

Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above Two Hundred Day Moving Average of $0.00
June 2, 2021 | americanbankingnews.com

Here's Why "Trend" Investors Would Love Betting on Hikma Pharmaceuticals Plc (HKMPF)
May 24, 2021 | finance.yahoo.com

A more powerful naloxone is on the way. The question is whether it’s needed.
May 17, 2021 | msn.com

Hikma makes strong start to year, receives approval for opioid treatment
April 30, 2021 | msn.com

Hikma Pharma Issues Trading Update; Announces FDA Approval Of KLOXXADO
April 30, 2021 | nasdaq.com

Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region
April 29, 2021 | finance.yahoo.com

Hyloris Pharmaceuticals SA: Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic IV
April 28, 2021 | finanznachrichten.de

See More Headlines

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolLON:HIK
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.hikma.com
Phone+44-20-73992760
Employees8,600
Year FoundedN/A

Sales & Book Value

Annual Sales£2.34 billion
Price / Sales2.36
Cash FlowGBX 143.11 per share
Price / Cash Flow16.68
Book ValueGBX 926.40 per share
Price / Book2.58

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares231,453,000
Market Cap£5.52 billion
Next Earnings Date8/6/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.48 out of 5 stars

2.5 Analyst's Opinion

Consensus Rating
Hikma Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 2,717.50, Hikma Pharmaceuticals has a forecasted upside of 13.8% from its current price of GBX 2,387.
Amount of Analyst Coverage
Hikma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Hikma Pharmaceuticals has received 767 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hikma Pharmaceuticals has received 619 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hikma Pharmaceuticals has received 55.34% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote “Outperform” if you believe HIK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.8 Dividend Strength

Dividend Yield
Hikma Pharmaceuticals has a dividend yield of 1.50%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Hikma Pharmaceuticals does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Hikma Pharmaceuticals is 0.36%. This payout ratio is at a healthy, sustainable level, below 75%.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.

1.3 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Hikma Pharmaceuticals is 18.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 30.24.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hikma Pharmaceuticals is 18.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 43.86.
Price to Book Value per Share Ratio
Hikma Pharmaceuticals has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

Is Hikma Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Hikma Pharmaceuticals stock.
View analyst ratings for Hikma Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Hikma Pharmaceuticals?

Wall Street analysts have given Hikma Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hikma Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Hikma Pharmaceuticals' next earnings date?

Hikma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Hikma Pharmaceuticals.

How has Hikma Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Hikma Pharmaceuticals' stock was trading at GBX 1,828.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HIK shares have increased by 30.5% and is now trading at GBX 2,387.
View which stocks have been most impacted by COVID-19.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Thursday, February 25th. Shareholders of record on Thursday, March 18th will be given a dividend of GBX 0.34 per share on Monday, April 26th. This represents a dividend yield of 1%. The ex-dividend date is Thursday, March 18th. This is an increase from Hikma Pharmaceuticals's previous dividend of GBX 0.16. The official announcement can be seen at this link.
View Hikma Pharmaceuticals' dividend history.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals pays an annual dividend of GBX 0.46 per share and currently has a dividend yield of 1.50%. The dividend payout ratio of Hikma Pharmaceuticals is 0.36%. This payout ratio is at a healthy, sustainable level, below 75%.
View Hikma Pharmaceuticals' dividend history.

What price target have analysts set for HIK?

5 analysts have issued 1 year price objectives for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 2,600 to GBX 2,860. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 2,717.50 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price.
View analysts' price targets for Hikma Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:

Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 64, Pay $3.01M)
Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 52, Pay $3.72M)
Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 63, Pay $2.16M)
Mr. Khalid Waleed Hosny Al Nabilsi, Chief Financial Officer (Age 49)
Ms. Henriette Nielsen, Exec. VP of Bus. Operations
Dr. Shahin Fesharaki, Chief Scientific Officer
Mr. Hussein Arkhagha, Chief Counsel
Mr. Bassam Wael Rushdi Kanaan, Exec. VP of Corp. Devel. and M&A (Age 56)
Ms. Susan Ringdal, Exec. VP of Strategic Planning & Global Affairs
Ms. Majda Labadi, Exec. VP of Organisational Devel.

Who are some of Hikma Pharmaceuticals' key competitors?

Some companies that are related to Hikma Pharmaceuticals include MERCK Kommanditgesellschaft auf Aktien (MRK), Bausch Health Companies (BHC), Canopy Growth (WEED), Evotec (EVT), Aphria (APHA), Leaf Mobile (LEAF), Aurora Cannabis (ACB), OrganiGram (OGI), HEXO (HEXO), Knight Therapeutics (GUD), HLS Therapeutics (HLS), Benchmark (BMK), Amryt Pharma (AMYT), The Supreme Cannabis (FIRE) and ICC Labs (ICC).
View all of HIK's competitors.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 2,387.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals has a market capitalization of £5.52 billion and generates £2.34 billion in revenue each year.

How many employees does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals employs 8,600 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

Where are Hikma Pharmaceuticals' headquarters?

Hikma Pharmaceuticals is headquartered at 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.

This page was last updated on 6/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here